Core Viewpoint - Cat's Eye Entertainment reported a significant decline in financial performance for the year ending December 31, 2024, with total revenue dropping by 14.2% to 4.082 billion yuan, primarily due to poor performance in the film market [1] Financial Performance - Total revenue for 2024 was 4.082 billion yuan, a decrease of 14.2% year-on-year [1] - Operating profit fell to 196 million yuan, down 82.2% from the previous year [1] - Net profit decreased by 80% to 182 million yuan [1] - Revenue from entertainment content services and online ticketing services, which typically account for over 45% of total revenue, both saw approximately 15% declines [1] Cost and Expenditure - Revenue cost slightly increased by 3.6% to 2.457 billion yuan [1] - Sales and marketing expenses rose by 11.5% to 939 million yuan [1] - Other cost expenditures remained stable [1] Film Market Impact - The decline in performance was largely attributed to the underwhelming market performance of films in which Cat's Eye participated, leading to a drop in entertainment content service revenue from 2.3 billion yuan in 2023 to 1.959 billion yuan in 2024 [2] - The overall film market in 2024 saw a total box office of 42.502 billion yuan, a decrease of 22.6% from 2023, with total audience attendance dropping by 22.4% [2] Online Ticketing Services - Online ticketing service revenue decreased from 2.258 billion yuan in 2023 to 1.921 billion yuan in 2024, attributed to the overall decline in the film market [3] - Despite the decline in ticketing revenue, the company reported record high GMV for offline performances, with a 90% year-on-year increase in concert ticketing GMV [3] Future Outlook - Cat's Eye remains optimistic about 2025, citing a strong start to the film market with a total box office exceeding 24.2 billion yuan by March 27, 2025, driven by successful releases during the Spring Festival [5] - The company has several films scheduled for release in 2025, including "Dumpling Queen" and "Panda Plan 2," which are expected to contribute positively to future revenues [5] - Cat's Eye plans to enhance its long-term investment in the performance business and expand overseas business cooperation to seek new growth opportunities [6]

本周关注点 股本股东变化 近日ST盛屯披露，截至2025年2月28日公司股东户数为13.32万户，较1月31日减少25.0户，减幅为 0.02%。户均持股数量由上期的2.32万股增加至2.32万股，户均持股市值为11.14万元。 业绩披露要点 ST盛屯2024年年报显示，公司主营收入257.3亿元，同比上升5.21%；归母净利润20.05亿元，同比上升 657.63%；扣非净利润18.25亿元，同比上升580.9%；其中2024年第四季度，公司单季度主营收入80.73 亿元，同比上升32.42%；单季度归母净利润3.05亿元，同比上升929.53%；单季度扣非净利润-6642.34万 元，同比下降393.86%；负债率54.97%，投资收益-2550.97万元，财务费用5.48亿元，毛利率19.5%。 公司公告汇总利润分配方案 截至2025年3月28日收盘，ST盛屯（600711）报收于5.74元，较上周的6.04元下跌4.97%。本周，ST盛屯 3月24日盘中最高价报6.19元。3月28日盘中最低价报5.66元。ST盛屯当前最新总市值177.4亿元，在能源 金属板块市值排名6/13，在两市A股市值排名897 ...

Group 1 - The company reported a revenue of RMB 299 million for the year ending December 31, 2024, representing a year-on-year growth of 43.82% [1] - The company incurred a loss attributable to shareholders of RMB 237 million [1] - Research and development expenditure amounted to RMB 135 million, reflecting a year-on-year increase of 4.39% [1] Group 2 - The company aims to provide automated, standardized, and intelligent assisted reproductive medical devices to improve success rates and operational efficiency for medical institutions [2] - The assisted reproductive technology sector is experiencing rapid development, with the company focusing on a "Live" core concept to deliver dynamic, real-time, and interconnected data experiences throughout the entire process [2] - The company has established a comprehensive product line covering the entire assisted reproduction industry chain, including reagents, consumables, instruments, and equipment, positioning itself as one of the few global suppliers with a full industry product offering [2]

Core Insights - The company reported a revenue of 5.505 billion yuan for the year ending December 31, 2024, representing a year-on-year increase of 7.21% [1] - Net profit attributable to shareholders reached 281 million yuan, a significant increase of 75.19% year-on-year, with basic earnings per share at 0.179 yuan [1] Group 1: Revenue and Profit Growth - Export sales revenue increased to 1.676 billion yuan in 2024 from 1.396 billion yuan in 2023, marking a year-on-year growth of 20.1% and accounting for 30.5% of total revenue [1] - The collective procurement business achieved sales revenue of 1.351 billion yuan, up from 1.136 billion yuan in 2023, reflecting an 18.9% year-on-year increase and a business share of 24.6% [1] Group 2: Strategic Initiatives and Operational Improvements - The company emphasized integrated value chain business models and multi-channel layout advantages to strengthen its leading position in the export market [1] - Continuous efforts in cost reduction and efficiency enhancement have led to significant improvements in overall operational management [1] - The company has focused on enhancing its research and development investments and optimizing resource allocation, resulting in rapid growth in new product sales [2] Group 3: Product and Market Development - The proportion of revenue from deep-processed products increased to 53.7% of total revenue, indicating a strengthened ability to withstand market fluctuations [2] - The company has implemented a comprehensive cost control system in the food processing segment, improving cost management effectiveness [2]

Core Viewpoint - MicroPort Medical's 2024 annual performance shows a revenue of $1.031 billion, with a year-on-year growth of 8.5%, and a significant reduction in net loss to $214 million, down 55.2% from the previous year [1][2] Group 1: Financial Performance - Revenue for the reporting period reached $1.031 billion, reflecting a 10% year-on-year growth when excluding foreign exchange impacts [1] - The net loss narrowed significantly, attributed to a strong performance in overseas business, which saw an 85% year-on-year increase in revenue [1] - Total expenses for sales, management, and R&D decreased by $216.5 million, a 24% reduction year-on-year, with the operating expense ratio dropping by 29 percentage points [1] Group 2: Strategic Initiatives - The company has established a global commercialization platform to facilitate rapid market entry and sales of products developed in China, covering over 20,000 hospitals in more than 100 countries and regions [2] - The company received 58 first-time registration certificates for Class III medical devices from the National Medical Products Administration of China and 249 first-time registration certificates in 43 overseas markets [2] - The focus remains on enhancing financial health, concentrating on core businesses, and promoting high-quality and stable business development [2]

智通财经APP讯，深圳控股(00604)发布截至2024年12月31日止年度业绩，集团收益155.67亿港元，同比 减少1.67%;股东应占亏损18.23亿港元，同比扩大597.25%;每股亏损20.48港仙。 在市场持续下行的情况下，集团持续创新推动招商，写字楼及商圈进一步提质升级。集中商业年内新签 约200家品牌商户，续签80余家;深业上城做强"首发经济"，新增30家全国及区域首店，品牌调改率达 41%，写字楼世界500强企业累计达13家，稳居深圳第二。集团持续对持有物业升级改造，在消除老旧 物业重大风险隐患同时提升资产价值。年内，集团物业投资收入约13.8亿港元，整体出租率90.8%，明 显优于市场水平。 现代农业方面，集团高标准建设现代化农业产业园，新丰农业产业园种植面积近3500亩，成功试种洋蓟 等高价值作物，全年农产品产量300余万斤。大鹏、南澳、新丰等"四季"农旅项目加速落地。先进制造 方面，创新载体建设提速提效，晶华公司获批国家级专精特新"小巨人"企业，获授权发明专利1项，实 用新型专利9项，启动越南生产基地建设，加快海外布局。 集团大力推动园区业务转型升级，推进"小而美"标杆园区运营，以创智 ...

"未来房地产行业会从高周转的增量发展模式转向精细化的存量运营模式。在这样的背景下，以非住为 主的商业物业管理企业，存在机会和挑战。"3月27日，在卓越商企服务集团有限公司(以下简称"卓越商 企服务")业绩说明会上，董事会主席兼执行董事李晓平表示。 同日，卓越商企服务发布的2024年"成绩单"显示，在市场压力下，公司维持稳健表现，2024年实现营收 42.3亿元，较去年同期增长8%，归母净利润达到3.12亿元，同比实现3%的增长，呈现筑底企稳态势。 从增长的动因来看，公司非住物业第三方的在管面积占比保持在60%以上，第三方业务仍然是核心引 擎。 在业绩说明会上，卓越商企服务执行董事、首席执行官杨志东表示，2024年公司全年新签的第三方合同 总额首次突破18.8亿元，创下历史新高。在高端制造、算力和数据中心等重点业态的市场占有率稳步提 升，与战略客户的合作持续深化。 卓越商企首席财务官兼联席公司秘书贾杰在业绩说明会上表示，在经历2023年去地产化的较大调整后， 公司2024年的业绩已企稳回升，毛利润和归母净利均取得增长，关联交易收入占比进一步降低，第三方 业务快速增长，独立性进一步增强。 "成绩来之不易，但这充分 ...

Group 1 - The company has entered into a preliminary agreement with Ningbo Zhoushan Port for the investment and implementation of the G92 Hangzhou Bay Ring Expressway project, specifically the section from Qijia Mountain in Ningbo to Jintang in Zhoushan, with an estimated investment of approximately RMB 15.985 billion [1] - The project will be funded with 45% as project capital, amounting to approximately RMB 7.193 billion, with the company and Ningbo Zhoushan Port contributing a combined 60% of the project capital [1] - A new company will be established to manage the project, which will have the concession rights for investment, financing, construction, operation, and management [1] Group 2 - The G92 Hangzhou Bay Ring Expressway project will span approximately 18.052 kilometers, connecting Ningbo and Zhoushan, and includes a 11.604-kilometer underwater tunnel and multiple interchanges [2] - This project is expected to enhance the traffic capacity and service level of the cross-sea passage between Ningbo and Zhoushan, alleviating traffic pressure on the existing cross-sea bridge and promoting regional economic and social development [2] - As the longest underwater tunnel road in Zhejiang Province, this project will help the company establish itself as a benchmark in the industry, enhancing its strategic position and reputation within the high-grade highway network [2]

智通财经APP讯，康圣环球(09960)发布截至2024年12月31日止年度业绩，该集团取得收入人民币9.28亿 元，毛利4.4亿元，研发成本1.06亿元，净亏损6068.1万元，每股亏损5.77分。 我们的毛利较同期下降，主要是因为由于收入下降3970万元以及固定资产投入的增加，相较2023年，集 团新建了上海实验室和广州实验室。毛利率较2023年上升，得益于产品结构的改善、成本控制、及效率 的提升。 2024年，我们坚持科研投入，以创新驱动发展，在精准医疗的相关科学技术及临床应用研究方面取得了 丰富的原创成果，为行业发展注入了强大动力，亦为我们的长远发展奠定了坚实基础。年内，集团科研 部门发表文章12篇(其中SCI收录5篇，中文核心期刊7篇)，实现1项著作权授权，申请了47项专利，24项 授权。集团共计新增研发检测项目264项，其中分子生物学检测技术相关项目130项，流式细胞术检测技 术相关项目42项，细胞遗传检测技术相关项目26项，病理检测技术相关项目17项。 2024年，中国对医疗行业的监管力度不断强化，第三方医检行业在政策引导下加速迈向规范化、健康化 与可持续发展的新阶段，行业整体进入深度调整与规範 ...

3月27日，山西建筑行业首个上市公司山西安装集团发布了2024年度业绩报告。 公告显示，截至2024年12月31日止年度业绩，该集团取得营业收入人民币122.43亿元（单位下同），同比增加11.59%；归属于母公司股东的净利润1.53亿 元，同比减少0.99%；每股基本盈利0.11元，拟分派股息每10股股份0.04537元。 据公开信息显示，2024年，山西安装集团以超450亿元的合同签订额，保持了高质量发展的稳健态势。其中，在山西市场新签合同额超164亿元，并拿下多 个重要项目。 例如，以山西天星煤气化有限公司年产101万吨焦炭及8万吨LNG新能源项目、浮山县污水处理厂提质改造项目、全国一体化算力网络国家枢纽节点山西 枢纽（太原）项目、长治高新区新材料产业基地项目为代表的121个项目先后落地山西。 除了山西市场外，山西安装集团新签项目遍布全国26个省，合同额达260.45亿元。宝看了位于新疆的明阳拉萨市尼木县50MW光储牧光互补光伏发电总承 包项目，位于中原的郑州航空港经济综合实验区绿轴印象项目，位于辽东地区的阜新恒久安泰电解液项目等。 | 財務摘要 | | | | | --- | --- | --- | ...